DAX24.539 +0,2%Est505.850 +1,0%MSCI World4.343 -0,1%Top 10 Crypto13,05 -0,6%Nas23.236 ±-0,0%Bitcoin79.117 +1,3%Euro1,1685 -0,3%Öl60,22 -1,0%Gold4.420 +2,1%

Gensight Biologics SA Aktie

Kaufen

Verkaufen

Aktien-Sparplan anlegen Aktien-Sparplan anlegen

0,1110 EUR +0,0004 EUR +0,36 %

09:08:23

STU

0,1140 EUR +0,0096 EUR +9,20 %

02.01.2026

PAR

Gensight Biologics SA jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Bei einem anderen Broker handeln

Smartphone

Marktkap.25,14 Mio. EUR

Div. Rendite0,00%

WKNA2ANGZ

ISINFR0013183985

SymbolGSGTF

Gensight Biologics SA Aktien News

Sortieren:Datum Meistgelesen

18.12.24BusinesswireGenSight Biologics Provides Update on Regulatory Discussions and Financial Situation

13.11.24BusinesswireGenSight Biologics Announces Submission of LUMEVOQ® Dossier to ANSM to Prepare for Restart of Early Access Program in France

28.10.24BusinesswireGenSight Biologics Announces Publication of Meta-Analyses Showing Better Outcomes for ND4-LHON Patients Treated with LUMEVOQ®

WerbungGensight Biologics SA-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

24.10.24BusinesswireGenSight Biologics Reports Cash Position as of September 30, 2024, and Provides Business Update

17.10.24BusinesswireGenSight Biologics Announces LUMEVOQ® Scientific Updates at AAO 2024

23.09.24BusinesswireGenSight Biologics Reports Interim Financial Results for the First Half of 2024, Provides Business Updates

23.07.24BusinesswireGenSight Biologics Reports Cash Position as of June 30, 2024, and Provides Business Update

11.07.24BusinesswireGenSight Biologics Launches Newsletter for Retail Investors

20.06.24BusinesswireGenSight Biologics Renegotiates Financial Obligations and Provides Operational Updates

04.06.24BusinesswireGenSight Biologics to Present at Upcoming Medical Conferences and Stakeholder Meetings

03.06.24BusinesswireGenSight Biologics Appoints William Monteith to its Board of Directors

18.04.24BusinesswireGenSight Biologics Announces the Filing of its 2023 Universal Registration Document

04.04.24BusinesswireGenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update

04.04.24BusinesswireGenSight Biologics Announces its 2024 Financial Calendar

22.03.24BusinesswireGenSight Biologics Reports Full Year 2023 Consolidated Financial Results

20.03.24BusinesswireGenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections Four Years After One-Time Administration

12.03.24BusinesswireGenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024

06.03.24BusinesswireGenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024

15.03.23BusinesswireGenSight Biologics Announces Presentation of LUMEVOQ® Efficacy and Safety Data from Early Access Programs for ND4-LHON Patients at NANOS 2023

13.03.23BusinesswireGenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral LUMEVOQ® Injections at 3-Year Follow-Up of REFLECT Phase III Trial

09.03.23BusinesswireGenSight Biologics Announces Publication of LUMEVOQ® Safety Data over 5-Year Period in renowned Peer-Reviewed American Journal of Ophthalmology

13.02.23BusinesswireGenSight Biologics Announces 1 Year Safety Data and Efficacy Signals from PIONEER Phase I/II Clinical Trial of GS030, an Optogenetic Treatment Candidate for Retinitis Pigmentosa

Gensight Biologics SA News

Gensight Biologics SA News: auf dieser Seite finden Sie alle Gensight Biologics SA News und Nachrichten zur Gensight Biologics SA Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Gensight Biologics SA News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Gensight Biologics SA News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.